TNFRSF11A and bone metastasis: Importantly, the survival advantage of denosumab observed in the clinical study of lung cancer bone metastasis patients occurred in patients either with or without visceral metastasis, suggesting that a mechanism beyond the bone targeted effect of RANK blockade may be operative (Scagliotti et al. 2012).